UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Aug

    07

    New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email

    Apr

    28

    UCB Announces PDUFA Date for Bimekizumab

    Read More Share:linkedin| twitter| email

    Apr

    23

    "The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email

    Apr

    23

    UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

    UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 

    Read More Share:linkedin| twitter| email

    Apr

    16

    UCB Showcases New Research at the 73rd American Academy of Neurology Annual Meeting to Demonstrate Broad Neurology Leadership and Future Portfolio

    Read More Share:linkedin| twitter| email

    Feb

    25

    UCB - Sustaining Growth, Now and Into the Future

    Read More Share:linkedin| twitter| email

    Feb

    23

    UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

    Read More Share:linkedin| twitter| email

    Feb

    05

    The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email

    Jan

    12

    UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy

    Read More Share:linkedin| twitter| email

    Nov

    30

    World's Leading Life Science Companies Now Enrolling COMMUNITY, a Global, Platform Trial for Hospitalized Patients with COVID-19

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)